Abstract
Hepatitis C virus (HCV) poses a major public health problem world wide. The introduction of combined therapy (interferon and ribavirin) and the recent development of pegylated interferon have offered the opportunity to alter the natural history of HCV, potentially reducing morbidity and mortality. Until recently, treatment has been confined to larger Australian cities. This paper describes the establishment of a clinic for the treatment of HCV in a regional Australian city. The facilities of the sexual health clinic were utilised. Factors contributing to the success of the clinic include the specialist nurse, a multidisciplinary approach, and the service model of shared care with general practitioners. The patient population and the outcomes of managing HCV in a regional centre are described. The sustained viral response rate is comparable to the published data from specialist centres.
Full Text
The Full Text of this article is available as a PDF (118.8 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Booth J. C., O'Grady J., Neuberger J., Thr Royal College of Physicians of London and the British Society of Gastroenterology Clinical guidelines on the management of hepatitis C. Gut. 2001 Jul;49 (Suppl 1):I1–21. doi: 10.1136/gut.49.suppl_1.I1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Chander Geetanjali, Sulkowski Mark S., Jenckes Mollie W., Torbenson Michael S., Herlong H. Franklin, Bass Eric B., Gebo Kelly A. Treatment of chronic hepatitis C: a systematic review. Hepatology. 2002 Nov;36(5 Suppl 1):S135–S144. doi: 10.1053/jhep.2002.37146. [DOI] [PubMed] [Google Scholar]
- Di Bisceglie Adrian M., Hoofnagle Jay H. Optimal therapy of hepatitis C. Hepatology. 2002 Nov;36(5 Suppl 1):S121–S127. doi: 10.1053/jhep.2002.36228. [DOI] [PubMed] [Google Scholar]
- Heathcote E. J., Shiffman M. L., Cooksley W. G., Dusheiko G. M., Lee S. S., Balart L., Reindollar R., Reddy R. K., Wright T. L., Lin A. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med. 2000 Dec 7;343(23):1673–1680. doi: 10.1056/NEJM200012073432302. [DOI] [PubMed] [Google Scholar]
- McCaw R., Moaven L., Locarnini S. A., Bowden D. S. Hepatitis C virus genotypes in Australia. J Viral Hepat. 1997 Sep;4(5):351–357. doi: 10.1046/j.1365-2893.1997.00060.x. [DOI] [PubMed] [Google Scholar]
- Nishiguchi S., Shiomi S., Nakatani S., Takeda T., Fukuda K., Tamori A., Habu D., Tanaka T. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet. 2001 Jan 20;357(9251):196–197. doi: 10.1016/S0140-6736(00)03595-9. [DOI] [PubMed] [Google Scholar]
- Schramm T. M., Lawford B. R., Macdonald G. A., Cooksley W. G. Sertraline treatment of interferon-alfa-induced depressive disorder. Med J Aust. 2000 Oct 2;173(7):359–361. doi: 10.5694/j.1326-5377.2000.tb125687.x. [DOI] [PubMed] [Google Scholar]
- Weiland O. New pieces to the hepatitis C treatment puzzle. J Hepatol. 2000 Sep;33(3):482–484. doi: 10.1016/s0168-8278(00)80287-1. [DOI] [PubMed] [Google Scholar]
- Younossi Z. M., Boparai N., Price L. L., Kiwi M. L., McCormick M., Guyatt G. Health-related quality of life in chronic liver disease: the impact of type and severity of disease. Am J Gastroenterol. 2001 Jul;96(7):2199–2205. doi: 10.1111/j.1572-0241.2001.03956.x. [DOI] [PubMed] [Google Scholar]